Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Sponsor: Boehringer Ingelheim
A PHASE4 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2023 — Jan 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2023 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Jan 2018 [monthly]
Completed PHASE4
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alytus, Lithuania, Aylesbury, United Kingdom, Bratislava, Slovakia, Bs As, Argentina, Buenos Aires, Argentina, Buenos Airess, Argentina, Charleston, United States, Coeur d'Alene, United States, Greenisland, United Kingdom, Kaunas, Lithuania and 25 more location s